ID: ALA5206894

Max Phase: Preclinical

Molecular Formula: C19H14ClNS

Molecular Weight: 323.85

Associated Items:

Representations

Canonical SMILES:  Clc1ccc2c(c1)N(Cc1ccccc1)c1ccccc1S2

Standard InChI:  InChI=1S/C19H14ClNS/c20-15-10-11-19-17(12-15)21(13-14-6-2-1-3-7-14)16-8-4-5-9-18(16)22-19/h1-12H,13H2

Standard InChI Key:  UINSXUPEARVSMF-UHFFFAOYSA-N

Associated Targets(Human)

20S proteasome 530 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 323.85Molecular Weight (Monoisotopic): 323.0535AlogP: 6.14#Rotatable Bonds: 2
Polar Surface Area: 3.24Molecular Species: HBA: 2HBD: 0
#RO5 Violations: 1HBA (Lipinski): 1HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: CX LogP: 6.18CX LogD: 6.18
Aromatic Rings: 3Heavy Atoms: 22QED Weighted: 0.56Np Likeness Score: -1.35

References

1. Staerz SD, Jones CL, Tepe JJ..  (2022)  Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of α-Synucleinopathies.,  65  (9.0): [PMID:35476454] [10.1021/acs.jmedchem.1c02158]

Source